However, it is likely that, after the initial tumor response, secondary alterations in melanoma cells may contribute to the development of acquired resistance to vemurafenib and other type I RAF inhibitors with specific antitumor activity against mutated BRAF, such as dabrafenib (previously GSK2118436) [5]. This evidence concerns the gene BRAF and neoplasm.